Overview

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2020-03-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in insulin naïve adult Chinese participants with Type 2 Diabetes Mellitus (T2DM) on 2 or more oral antihyperglycemic medications (OAMs). Participants will continue their OAMs throughout the study.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin Glargine